Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lipitor’s U.K. Exclusivity Affirmed In Appellate Decision

This article was originally published in The Pink Sheet Daily

Executive Summary

Ranbaxy’s generic atorvastatin may not launch in the U.K. until November 2011, Pfizer says.

You may also be interested in...



Lipitor Generics Could Come 15 Months Earlier Than Anticipated After Patent Deemed Invalid

Pfizer says “technical defect” in patent could be corrected with U.S. Patent and Trademark Office.

Lipitor Generics Could Come 15 Months Earlier Than Anticipated After Patent Deemed Invalid

Pfizer says “technical defect” in patent could be corrected with U.S. Patent and Trademark Office.

Lipitor Is Pound-Wise Versus Generic Zocor, Pfizer IDEAL Cost Study Says

When total healthcare costs are considered, atorvastatin is more cost-effective than simvastatin even when Zocor is discounted 50% from its current price, Pfizer analysis says.

Related Content

Topics

UsernamePublicRestriction

Register

LL111799

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel